Safety and Effectiveness of Three Anti-HIV Drugs Combined in One Pill (Trizivir)

Phase 3

• Conditions: HIV Infections

• Registration Number: NCT00004981
• Lead Sponsor: Glaxo Wellcome

Brief Summary

The purpose of this study is to look at the safety and effectiveness of a pill called Trizivir that is a combination of three anti-HIV drugs (zidovudine, lamivudine, and abacavir). Zidovudine and lamivudine are often given combined in one pill (Combivir). In this study, Trizivir will be compared to Combivir plus abacavir.

Detailed Description

Patients are randomized to receive either the triple combination tablet (Trizivir) or to receive Combivir plus abacavir as a separate tablet. Patients take their study medications for 24 weeks.

Study Timeline

• Study First Submitted: 2000-03-13
• Status Verified: 2001-06
• Study First Submitted QC: 2001-08-30
• Study First Posted: 2001-08-31
• Last Update Submitted: 2005-06-23
• Last Update Posted: 2005-06-24

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 230

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: Not specified

Trial Locations

Locations (25)

AIDS Healthcare Foundation; 🇺🇸 Los Angeles, California, United States

Tower Infectious Disease Med Ctr; 🇺🇸 Los Angeles, California, United States

Robert Scott MD; 🇺🇸 Oakland, California, United States

St Lukes Medical Group; 🇺🇸 San Diego, California, United States

Georgetown Univ Med Ctr; 🇺🇸 Washington, District of Columbia, United States

Whitman Walker Clinic; 🇺🇸 Washington, District of Columbia, United States

Univ of Miami School of Medicine; 🇺🇸 Miami, Florida, United States

Specialty Med Care Ctrs of South Florida Inc; 🇺🇸 Miami, Florida, United States

Saint Josephs Comprehensive Research Institute; 🇺🇸 Tampa, Florida, United States

AIDS Research Consortium of Atlanta; 🇺🇸 Atlanta, Georgia, United States

Scroll for more (15 remaining)